Profile
QNTM ZTS TAK HLN TEVA ITCI
Company Name Quantum BioPharma Ltd. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $70.86M $73.16B $47.84B $46.83B $19.50B $14.05B
Employees 0.00K 13.80K 49.28K 24.56K 37.00K 0.86K
CEO Zeeshan Saeed Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
QNTM ZTS TAK HLN TEVA ITCI
Quant Rating Score 2 3 3 3 1 1
Quant Rating Sell Neutral Neutral Neutral Strong Sell Strong Sell
Trading
QNTM ZTS TAK HLN TEVA ITCI
Last Close $24.37 $157.23 $14.97 $10.5 $17 $131.87
High 52 $35 $196.48 $15.39 $11.41 $22.77 $131.91
Low 52 $2.9 $144.45 $12.89 $8.26 $12.82 $67.99
Price vs. 52 Week High -30.37 % -19.98 % -2.73 % -7.98 % -25.34 % -0.03 %
Price vs. 52 Week Low 740.34 % 8.85 % 16.14 % 27.12 % 32.61 % 93.95 %
Total Return
QNTM ZTS TAK HLN TEVA ITCI
1 Month Return 111 % -3.29 % 2.75 % -5.75 % 0.24 % 0 %
3 Month Return 251.15 % -3.43 % -0.33 % 4.48 % 8.35 % 0.14 %
6 Month Return 598.28 % -5.01 % 13.93 % 7.8 % -24.85 % 53.34 %
9 Month Return 548.14 % -19.32 % 2.18 % -0.85 % -4.17 % 80.13 %
YTD Return 562.23 % -3.5 % 13.07 % 10.06 % -22.87 % 57.89 %
1 Year Return 0 % -8 % 15.87 % 23.53 % 4.62 % 85.5 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
QNTM ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.13 % 4.52 % 0.01 % - -
Dividend Paid and Capex Coverage Ration (TTM) -2600795.87 % 2 % 1.65 % - 2.53 % -227.26 %
Dividend Per Share (TTM) - 1.86 % 196 % 0.05 % - -
Payout Ratio (TTM) - 32.25 % 280.28 % - - -
Growth
QNTM ZTS TAK HLN TEVA ITCI
Asset Growth -2.03 % 0.76 % -9.55 % 87.69 %
Gross Profit Growth - -0.19 % 5.47 % 44.88 %
Revenue Growth - -0.61 % 4.4 % 46.62 %
Revenue 3 Year - 19.01 % 1.52 % 556.51 %
Revenue 5 Year - 33.95 % -5.5 % 600974.32 %
Revenue 10 Year - 33.95 % -38.45 % 32663.23 %
EBIT Growth 18.44 % 13.52 % -169.63 % 26.77 %
Net Income Growth 20.66 % 37.46 % -193.2 % 46.54 %
Net Income 3 Yeari Growth Per Share 80.97 % 4.91 % -482.97 % 79.29 %
Net Income 5 Yeari Growth Per Share 96.53 % 122.63 % -58.26 % 72.95 %
Net Income 10 Yeari Growth Per Share -3746.69 % 122.63 % -140.46 % 32.41 %
Operating Income Growth 32.17 % 10.52 % -169.98 % 26.77 %
Operating Cash Flow Growth (CFG) 36.49 % 9.57 % -8.85 % 41.08 %
Operating 3 Year CFG 84.33 % 71.6 % 52.26 % 77.79 %
Operating 5 Year CFG 95.21 % 196.04 % 123.59 % 69.4 %
Operating 10 Year CFG -962912.98 % 196.04 % -81.66 % 10.87 %
EPS Growth 57.5 % 45.45 % -190 % 50.68 %
EPS Diluted Growth 57.5 % 45.45 % -190 % 50.68 %
Book Value Per Share -56.68 % -1.63 % -30.36 % 80.54 %
Share Holder 3 Year Equity Growth Per Share -89.97 % -37.97 % -49 % 116.52 %
Share Holder 5 Year Equity Growth Per Share -96.98 % -40.16 % -62.86 % 215.14 %
Share Holder 10 Year Equity Growth Per Share 1847.3 % -40.16 % -82.6 % 164.65 %
Dividend Per Share Growth - 49.01 % - -
Dividend 3 Year Growth Per Share - -49.79 % - -
Dividend 5 Year Growth Per Share - -49.97 % -100 % -
Dividend 10 Year Growth Per Share - -49.97 % -100 % -
Debt Growth 143.2 % 6.83 % -10.29 % 0.25 %
Free Cash Flow Growth 36.49 % 16.27 % -11.05 % 40.95 %
Updated On 31 Dec 2024 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
QNTM ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM - 70.2 % 54.7 % 61.52 % 49.17 % 91.63 %
Return on Assets TTM -140.18 % 17.86 % 0.76 % 4.2 % -3.35 % -5.46 %
Return on Equity TTM -187.58 % 51.32 % 1.48 % 8.73 % -21.38 % -7.4 %
Return on Capital Employed TTM -380.95 % 32.08 % 3.75 % 7.74 % 1.59 % -10.05 %
Net Income Per EBT TTM 96.81 % 78.79 % 61.12 % 75.5 % 246.36 % 100.64 %
EBT Per Ebit TTM 124.82 % 92.99 % 40.08 % 86.58 % -120.28 % 63.57 %
EBIT Per Revenue TTM - 37.01 % 9.62 % 19.64 % 2.61 % -17.15 %
Cash Flow To Debt Ratio TTM -714.78 % 43.63 % 21.32 % - 7.47 % -430.93 %
Receivables Turnover TTM - 6.82 6.32 5.9 4.91 4.09
Payables Turnover TTM - 6.51 4.36 2.19 3.69 2.18
Inventory Turnover TTM 5.3 1.16 1.7 3.63 2.6 2.17
Fixed Asset Turnover TTM - 253.65 % 232.78 % 584.75 % 332.7 % 4569.25 %
Asset Turnover TTM - 65.87 % 32.15 % 32.73 % 43.25 % 49.79 %
Operating Cash Flow Per Share TTM -8.05 6.58 608.55 - 1.11 -0.71
Free Cash Flow Per Share TTM -8.05 5.1 443.26 - 0.67 -0.71
Cash Per Share TTM 552.53 % 384.5 % 24349.44 % 24.05 % 149.12 % 970.67 %
Operating Cash Flow Sales Ratio TTM - 31.71 % 21.01 % - 7.62 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 77.45 % 72.84 % - 60.43 % 100.44 %
Cash Flow Coverage Ratios TTM -714.78 % 43.63 % 21.32 % - 7.47 % -430.93 %
Price To Free Cash Flows Ratio TTM -7.74 32.07 9.73 - 25.68 -191.12
Price To Operating Cash Flows Ratio TTM -3.03 24.98 7.13 - 15.4 -185.85
Price Cash Flow Ratio TTM -3.03 24.98 7.13 - 15.4 -185.85
Income Statement (TTM)
QNTM ZTS TAK HLN TEVA ITCI
Revenue $0B $9.26B $4263.76B $11.23B $16.54B $0.68B
Gross Profit $0B $6.54B $2832.26B $6.95B $8.06B $0.62B
Gross Profit Ratio 0% 70.62% 66.43% 61.85% 48.74% 91.63%
EBITDA $-0.01B $3.87B $874.6B $2.51B $0.72B $-0.12B
Net Income $-0.01B $2.49B $144.07B $1.44B $-1.64B $-0.07B
EPS Diluted -12.49 5.47 45.58 0.32 -1.45 -0.72
Balance Sheet (MRQ)
QNTM ZTS TAK HLN TEVA ITCI
Long Term Debt $0B $5.39B $5029.93B $8.54B $16.3B $0.01B
Total Liabilities $0.01B $9.47B $7834.79B $18.09B $33.61B $0.22B
Total Equity $0.01B $4.77B $7274.01B $16.22B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.08B $0B $0.69B
Total Debt $0B $6.74B $4843.75B $10.1B $18.08B $0.02B
Total Assets $0.02B $14.24B $15108.79B $34.32B $39.33B $1.37B
Cash Flow Statement (TTM)
QNTM ZTS TAK HLN TEVA ITCI
Net Income $-0.01B $2.5B $144.07B $1.44B $-1.96B $-0.07B
Inventory $-0B $-0.04B $-115.74B $0.22B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-287.19B $-0.57B $0B $0B
Operating Cash Flow $-0.01B $2.95B $716.34B $2.3B $1.25B $-0.07B
Capital Expenditure $0B $-0.66B $-480.73B $-0.25B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.01
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.41
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 9.34
ALVOW Alvotech 1.5
AMPH Amphastar Pharmaceuticals, Inc. 23.57
AMRX Amneal Pharmaceuticals, Inc. 8.235
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 66.14
APUS Apimeds Pharmaceuticals US, Inc 1.66
AQST Aquestive Therapeutics, Inc. 3.24
ASRT Assertio Holdings, Inc. 0.6232
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 9.36
ETFs With Exposure to QNTM
Ticker ETF Name Weight Percentage Price
PSIL AdvisorShares Psychedelics ETF 11.8 14.15
Unlock